参考文献/References:
[1] 睢瑞芳,邹绚.遗传性视网膜疾病的基因诊断[J].眼科,2014,23(6):361-364.
SUI R F,ZOU X.Genetic diagnosis of hereditary retinal diseases [J].Ophthalmol CHN,2014,23(6):361-364.
[2] 王志玉,史爱云.视网膜挫伤兔模型的病理学观察[J].国际眼科杂志,2009,9(8):1469-1471.
WANG Z Y,SHI A Y.Pathological observation of rabbit model of retinal contusion [J].Int Eye Sci,2009,9(8):1469-1471.
[3] 夏阳,蔺云霞,徐玲.无黄斑病变近视患者黄斑区视网膜结构与视功能改变的相关性[J].眼科新进展,2020,40(5):457-460,465.
XIA Y,LIN Y X,XU L.Correlation between macular retinal structure and visual function in patients with myopia without maculopathy [J].Rec Adv Ophthalmol,2020,40(5):457-460,465.
[4] KUMARAN N,MOORE A T,WELEBER R G,MICHAELIDES M.Leber congenital amaurosis/early-onset severe retinal dystrophy:clinical features,molecular genetics and therapeutic interventions [J].Br J Ophthalmol,2017,101(9):1147-1154.
[5] MU W,LU H M,CHEN J,LI S,ELLIOTT A M.Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing [J].Mol Diagn,2016,18(6):923-932.
[6] ZICCARDI L,CORDEDDU V,GADDINI L,MATTEUCCI A,PARRAVANO M,MALCHIODI-ALBEDI F,et al.Gene therapy in retinal dystrophies [J].Int J Mol Sci,2019,20(22):5722.
[7] GáNDARA C,AFFLECK V,STOLL E A.Manufacture of third-generation lentivirus for preclinical use,with process development considerations for translation to good manufacturing practice [J].Hum Gene Ther Methods,2018,29(1):1-15.
[8] MADRAKHIMOV S B,YANG J Y,AHN D H,HAN J W,HA T H,PARK T K,et al .Peripapillary intravitreal injection improves AAV-mediated retinal transduction[J].Mol Ther Methods Clin Dev,2020,17:647-656.
[9] BARKER S E,BRODERICK C A,ROBBIE S J,DURAN Y,NATKUNARAJAH M,BUCH P,et al.Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice [J].J Gene Med,2009,11(6):486-497.
[10] VASCONCELOS H M Jr,LUJAN B J,PENNESI M E,YANG P,LAUER A K.Intraoperative optical coherence tomographic findings in patients undergoing subretinal gene therapy surgery [J].Int J Retina Vitreous,2020,6:13.
[11] JAYADEV C,DABIR S,VINEKAR A,SHAH U,VAID T,YADAV N K.Microscope-integrated optical coherence tomography:a new surgical tool in vitreoretinal surgery[J].Indian J Ophthalmol,2015,63(5):399-403.
[12] CIULLA T A,HUSSAIN R M,BERROCAL A M,NAGIEL A.Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases:a model for ocular gene therapy development [J].Expert Opin Biol Ther,2020,20(6):565-578.
[13] CAI S,THERATTIL A,VAJZOVIC L.Recent developments in pediatric retina [J].Curr Opin Ophthalmol,2020,31(3):155-160.
[14] PIERCE E A,BENNETT J.The status of RPE65 gene therapy trials:safety and efficacy [J].Cold Spring Harb Perspect Med,2015,5(9):a017285.
[15] 梁小芳,睢瑞芳,董方田.全色盲遗传学研究进展[J].中华实验眼科杂志,2015,33(8):764-767.
LIANG X F,SUI R F,DONG F T.Advances in genetics of total color blindness [J].Chin J Exp Ophthalmol,2015,33(8):764-767.
[16] PONTIKOS N,ARNO G,JURKUTE N,SCHIFF E,BA-ABBAD R,MAIKA S,et al.Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the United Kingdom [J].Ophthalmology,2020,127(10):1384-1394.
[17] BIRTEL J,HOLZ F G,HERRMANN P.Gene therapy approaches to a rare retinal disease:Choroideremia[J].Dtsch Arztebl Int,2020,117(3):30.
[18] TANNA P,STRAUSS R W,FUJINAMI K,MICHAELIDES M.Stargardt disease:clinical features,molecular genetics,animal models and therapeutic options[J].Br J Ophthalmol,2017,101(1):25-30.
[19] LENIS T L,HU J,NG S Y,JIANG Z,SARFARE S,LLOYD M,et al.Expression of ABCA4 in the retinal pigment epithelium and its implications for stargardt macular degeneration [J].Proc Natl Acad Sci USA,2018,115(47):e11120-e11127.
[20] PARKER M A,CHOI D,ERKER L R,PENNESI M E,YANG P,CHEGARNOV E N,et al.Test-retest variability of functional and structural parameters in patients with Stargardt disease participating in the SAR422459 gene therapy trial [J].Transl Vis Sci Technol,2016,5(5):10.
[21] VERBAKEL S K,VAN HUET R A C,BOON C J F,HOLLANDER A I D,COLLIN R W J,KLAVER C C W,et al.Non-syndromic retinitis pigmentosa [J].Prog Retin Eye Res,2018,66:157-186.
[22] JIANG P F,PENG J,OU C,YAO Z,TIAN Y.Experimental research progress of retinitis pigmentosa [J].Int Eye Sci,2020,20(6):970-973.
[23] RAO K N,LI L,ZHANG W,BRUSH R S,RAJALA R V,KHANNA H.Loss of human disease protein retinitis pigmentosa GTPase regulator (RPGR) differentially affects rod or cone-enriched retina [J].Hum Mol Genet,2016,25(7):1345-1356.
[24] LAVAIL M M,YASUMURA D,MATTHES M T,MATTHES M,YANG H,HAUSWIRTH W W,et al.Gene therapy for MERTK-associated retinal degenerations[J].Adv Exp Med Biol,2016,854:487-493.
[25] KUTLUER M,HUANG L,MARIGO V.Targeting molecular pathways for the treatment of inherited retinal degeneration[J].Neural Regen Res,2020,15(10):1784-1791.
[26] MATHUR P,YANG J.Usher syndrome:Hearing loss,retinal degeneration and associated abnormalities[J].Biochim Biophys Acta,2015,1852(3):406-420.
[27] WILLIAMS D S,LOPES V S.The many different cellular functions of MYO7A in the retina[J].Biochem Soc Trans,2011,39(5):1207-1210.
[28] MOLDAY R S,KELLNER U,WEBER B H.X-linked juvenile retinoschisis:clinical diagnosis,genetic analysis,and molecular mechanisms [J].Prog Retin Eye Res,2012,31(3):195-212.
[29] VIJAYASARATHY C,SUI R,ZENG Y,ZENG Y,YANG G X,XU F,et al.Molecular mechanisms leading to null-protein product from retinoschisin (RS1) signal-sequence mutants in X-linked retinoschisis (XLRS) disease [J].Hum Mutat,2010,31(11):1251-1260.
[30] MA Y,ZHANG L,HUANG X.Genome modification by CRISPR/Cas9 [J].FEBS ,2014,281(23):5186-5193.
[31] ZHANG J H,ADIKARAM P,PANDEY M,GENIS A,SIMONDS W F.Optimization of genome editing through CRISPR-Cas9 engineering [J].Bioengineered,2016,7(3):166-174.
[32] GARANTO A,CHUNG D C,DUIJKERS L,CORRAL-SERRANO J C,MESSCHAERT M,XIAO R,et al.In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery [J].Hum Mol Genet,2016,25(12):2552-2563.
[33] DONALDSON T N,JENNINGS K T,CHEREP L A,MCNEELA A M,DEPREUS F F,JODELKA F M,et al.Antisense oligonucleotide therapy rescues disruptions in organization of exploratory movements associated with Usher syndrome type 1C in mice [J].Behav Brain Res,2018,338:76-87.
[34] TRAPANI I,AURICCHIO A.Seeing the light after 25 years of retinal gene therapy [J].Trends Mol Med,2018,24(8):669-681.
[35] BERTSCH M,FLOYD M,KEHOE T,PFEIFER W,DRACK A V.The clinical evaluation of infantile nystagmus:what to do first and why?[J].Ophthalmic Genet,2017,38(1):22-33.